News

One intravitreal injection of QPI-1007 (Quark Pharmaceuticals) to treat nonarteritic anterior ischemic optic neuropathy (NAION) was safe with no serious adverse events in a phase I trial, and most patients gained 3 or more lines of vision, according to Bradley Katz, MD, PhD, who reported the results on behalf of the Quark Study Group.

More than 11,500 clinicians and researchers will gather in Orlando to learn more about leading eye and vision research at the 2014 meeting of the Association for Research in Vision and Ophthalmology.

Combined small-incision lenticule extraction (SMILE) and intrastromal collagen crosslinking (CXL) to treat forme fruste keratoconus is safe, efficient, accurate, predictable, and stable for treating keratoconus for at least 1 year, according to Enrique O. Graue Hernandez, MD, MSc.

Alimera Sciences’ recent resubmission of the new drug application (NDA) for its fluocinolone acetonide intravitreal implant (Iluvien) has been received by the FDA as a complete class 2 response to the agency’s October letter, and a prescription drug user fee act (PDUFA) goal date of Sept. 26 has been established.

Gonioscopy-assisted transluminal trabeculotomy is a circumferential trabeculotomy performed via a minimally invasive, ab interno approach. Results from follow-up of 6 to 12 months in a series of 85 adult eyes with uncontrolled glaucoma show high IOP lowering, along with a reduced need for medication.

The AREDS 1 and 2 studies provide important information about the role of ocular nutrition in AMD. However, to benefit patients, the findings must be condensed into clear and concise advice that will help them select appropriate vitamin supplements and follow a healthy lifestyle.

A randomized, double blind study of physicians who took part in the Physicians’ Health Study II found that those who received a daily multivitamin had a 9% lower risk of cataract - and a 14% lower risk of nuclear cataract- than those who received placebo. Given the prevalence of cataracts in the population at large, a 9% reduction in risk could have a significant public health impact.

Examining how nutrition affects vision, and how physicians need to encourage healthy diets that contain essential nutrients and antioxidants essential for healthy vision.

Primary outcome data from a phase III clinical trial evaluating aflibercept (Eylea, Regeneron) for macular edema (ME) due to branch retinal vein occlusion (BRVO) show that intravitreal treatment with the anti-VEGF agent was well tolerated and associated with significantly better improvements in visual acuity and central retinal thickness (CRT) than laser photocoagulation.

Novaliq GmbH has announced the commencement of a phase I study for its dry eye syndrome treatment, cyclosporine solution (CyclASol), following United States and European patent approval.

BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma-a subconjunctival Latanoprost controlled-release insert.

Congress has approved legislation delaying for 1 year a massive 24% Medicare fee cut, which had been scheduled to take effect April 1, as well as implementation of the ICD-10-CM coding system.